Literature DB >> 21911597

FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.

Andries J Hoitsma1, Ervin S Woodle, Daniel Abramowicz, Pieter Proot, Yves Vanrenterghem.   

Abstract

BACKGROUND: FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine.
METHODS: This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation.
RESULTS: Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increased incidence of macular oedema, transient decrease in heart rate and low rate of infections were seen in the FTY720 arm.
CONCLUSION: FTY720 combined with tacrolimus and steroids did not show a significant therapeutic advantage over MMF for the prevention of acute rejection in de novo renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911597     DOI: 10.1093/ndt/gfr503

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  17 in total

Review 1.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

2.  Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.

Authors:  Michael S Mulvihill; Kannan P Samy; Qimeng A Gao; Robin Schmitz; Robert P Davis; Brian Ezekian; Francis Leopardi; Mingqing Song; Tam How; Kyha Williams; Andrew Barbas; Bradley Collins; Allan D Kirk
Journal:  Am J Transplant       Date:  2019-04-12       Impact factor: 8.086

3.  Fingolimod and macular edema: Pathophysiology, diagnosis, and management.

Authors:  Sudha Cugati; Celia S Chen; Stewart Lake; Andrew W Lee
Journal:  Neurol Clin Pract       Date:  2014-10

Review 4.  Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Authors:  Leslie S Kean; Laurence A Turka; Bruce R Blazar
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

6.  Early tolerability and safety of fingolimod in clinical practice.

Authors:  Daniel Ontaneda; Claire Hara-Cleaver; Richard A Rudick; Jeffrey A Cohen; Robert A Bermel
Journal:  J Neurol Sci       Date:  2012-10-03       Impact factor: 3.181

Review 7.  Benefits versus risks of latest therapies in multiple sclerosis: a perspective review.

Authors:  Daniel Ontaneda; Daniela Di Capua
Journal:  Ther Adv Drug Saf       Date:  2012-12

8.  FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.

Authors:  Hong Yu; Bethany A Herbert; Michael Valerio; Leigh Yarborough; Li-Chien Hsu; Kelley M Argraves
Journal:  Lipids Health Dis       Date:  2015-07-04       Impact factor: 3.876

9.  Sphingolipids: a potential molecular approach to treat allergic inflammation.

Authors:  Wai Y Sun; Claudine S Bonder
Journal:  J Allergy (Cairo)       Date:  2012-12-18

Review 10.  Lymphatic disorders after renal transplantation: new insights for an old complication.

Authors:  Andrea Ranghino; Giuseppe Paolo Segoloni; Fedele Lasaponara; Luigi Biancone
Journal:  Clin Kidney J       Date:  2015-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.